Latest News - Amgen
Top Corporates Hub
Amgen
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
31.10.2025 13:00
Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA.
Insiders At Amgen Sold US$12m In Stock, Alluding To Potential Weakness
30.10.2025 11:00
Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...
Amgen (NASDAQ:AMGN) Seems To Use Debt Quite Sensibly
16.10.2025 12:00
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study
16.10.2025 05:59
Amgen Inc. (NASDAQ:AMGN) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is a California-based biopharmaceutical company. On October 3, Oppenheimer reaffirmed its Outperform rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $380. The firm highlighted Amgen’s solid performance and also reported that its VESALIUS-CV trial reached […]
Amgen (AMGN) Announces Launch of AmgenNow
14.10.2025 17:06
Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, which is backed by its intellectual property and brand reputation. On October 6, the company announced the launch of AmgenNow, which is a new direct-to-patient program starting with Repatha® (evolocumab). This comes after the […]
Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention
13.10.2025 12:43
Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or […]
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
13.10.2025 03:32
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
08.10.2025 13:00
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 S&P 500 Stocks to Target This Week and 1 Facing Challenges
08.10.2025 04:35
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Does Amgen’s Recent 4.7% Surge Signal Room for Growth in 2025?
08.10.2025 04:34
If you are scratching your head about whether to buy, sell, or just hold on to Amgen stock, you are not alone. The biotech giant has had an interesting run. Just last week, shares jumped 4.7%, capping off a month that saw a 4.2% gain. Year to date, Amgen has climbed an impressive 14.0%. That kind of momentum, especially after a softer 1-year return of -3.9%, has caught a lot of investors’ attention and triggered plenty of debate about what is next. Much of the recent optimism seems tied to...
Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online
06.10.2025 19:23
Biotech giant rushes to comply with Trump's drug price crackdown, joins Pfizer in avoiding tariff backlash
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
06.10.2025 15:09
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035
06.10.2025 13:53
Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and
Here's Why Amgen (AMGN) is a Strong Value Stock
06.10.2025 13:40
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings
06.10.2025 13:15
SANTA MONICA, Calif., October 06, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.
Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?
06.10.2025 13:00
Key Insights The projected fair value for Amgen is US$586 based on 2 Stage Free Cash Flow to Equity Current share price...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
06.10.2025 13:00
Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
02.10.2025 13:00
Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke. The landmark Phase 3 VESALIUS-CV trial enrolled over 12,000 high-risk patients, approximately 85% of whom were maintained on a high-intensity or moderate low-density lipoprotein cholesterol (LDL-C) reducing the
Amgen Inc (AMGN) Ramps Up Manufacturing Capacity in US, Amidst Hefty Tariffs
02.10.2025 06:55
Amgen Inc. (NASDAQ:AMGN) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 26, Reuters reported that global drugmakers are rushing to increase their manufacturing capacity in the United States as the Trump administration is imposing hefty tariffs on pharmaceutical imports. As a result, Amgen Inc. (NASDAQ:AMGN) is also ramping […]
Amgen (AMGN) Announces $650M Puerto Rico Facility Expansion
02.10.2025 06:33
Amgen Inc. (NASDAQ:AMGN) ranks among the top picks for a retirement portfolio. On September 26, Amgen Inc. (NASDAQ:AMGN) unveiled a $650 million upgrade to its manufacturing facility in Juncos, Puerto Rico, which is estimated to create around 750 additional jobs. The investment will help to improve medicine production capacities and incorporate innovative technology across the […]